The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular and vascular penile ...

Increasing evidence from cellular studies and animal models indicate protective effects of phosphodiesterase-5 (PDE5) inhibitors, drugs usually reserved as treatments of erectile dysfunction and ...

Introduction Recent controlled trials have assessed the efficacy of phospodiesterase-5 (PDE-5) inhibitors in secondary Raynaud's phenomenon (RP). However, the conclusions are conflicting, and whether ...

As we report herein, we have designed phosphonic acid-containing variants of our previously reported carboxylic acid-containing imidazopyrazine and imidazopyridine inhibitors and we have obtained ...

Introduction Phosphodiesterase-type 5 inhibitors (PDE5i) are the recommended first-line treatment for erectile dysfunction. Previous systematic reviews and meta-analyses suggest that they are a safe ...

uk-erlangen.de Objectives To investigate the disease-modifying effects of phosphodiesterase 4 (PDE4) inhibition in preclinical models ... Importantly, apremilast is already approved for the treatment ...

Phosphodiesterase inhibitors (also known as PDE5 inhibitors) are a class of drugs commonly used to treat ED. Two drugs in this class are Levitra (vardenafil) and Viagra (sildenafil). Levitra is no ...

A new study reports that mirodenafil, a newly developed oral phosphodiesterase type 5 ... with ED receiving the currently available PDE5 inhibitors cease treatment, as the drugs might not provide ...